Abstract: The present invention relates to a PCR product cloning vector applicable directly to the cloning of a PCR product. More precisely, the present invention relates to a PCR product cloning vector designed to be effective in use for blue/white colony selection and produced based on the restriction enzyme treatment process to generate non- complementary unpaired single overhang and a method for producing the same. According to the method of the present invention, the PCR product cloning vector designed to be advantageous for blue/white cloning selection can be produced with improved efficiency compared with the convention method.

Abstract: The present invention relates to compositions for removing a biofilm formed by Staphylococcus aureus, comprising a bacteriophage, such as Myoviridae family T4-like phage genus bacteriophage (Accession No: KCTC 11153BP, SAP-I) or Podoviridae family ?29-like virus genus bacteriophage (Accession No: KCTC11154BP, SAP-2), and lytic protein derived therefrom, that destroys the biofilm. Also disclosed are pharmaceutical compositions for the treatment of diseases caused by Staphylococcus aureus capable of forming biofilm.

Abstract: The present invention relates to a novel antimicrobial protein derived from bacteriophage having killing activity specific to Staphylococcus aureus, more precisely an antimicrobial protein originated from Podoviridae bacteriophage having killing activity specific to Staphylococcus aureus which is the causing agent of infectious disease in human and animals, a pharmaceutical composition for the prevention and treatment of infectious disease caused by Staphylococcus aureus, an antibiotic and a disinfectant containing the bacteriophage-originated antimicrobial protein as an active ingredient.

Abstract: The present invention relates to a novel bacteriophage, more precisely a Podoviridae bacteriophage having killing activity specific to Staphylococcus aureus which is the causing agent of infectious disease in human and animals, a pharmaceutical composition for the prevention and treatment of the disease caused by Staphylococcus aureus, an antibiotic and a disinfectant containing the bacteriophage as an active ingredient.

Abstract: The present invention relates to a lysin protein originated from bacteriophage, more precisely a lysin protein comprising the amino acid sequence represented by SEQ. ID. NO: 2 which has no harm to human and animals comprising eukaryotic cells owing to its specificity to bacteria and has broad antibacterial activity, and a pharmaceutical composition for the prevention and treatment of infectious disease caused by bacteria comprising the said lysin protein as an active ingredient.

Abstract: The present invention relates to a novel bacteriophage-originated protein having antimicrobial activity, more precisely an antimicrobial protein originated from lytic bacteriophage having killing activity specific to Staphylococcus aureus which is the causing agent of infectious diseases in human and animals, a pharmaceutical composition for the prevention and treatment of the disease caused by Staphylococcus aureus, an antibiotic and a disinfectant containing the bacteriophage-originated antimicrobial protein as an active ingredient.

Abstract: Disclosed is a centrifuging device with a detachable cover and a safeguard structure in which the cover of the centrifuging device can be completely separated from the housing; and the safeguard structure can prevent a rotor from becoming separated from a drive shaft during operation due to flange defection and prevent the fractured pieces of the rotor from springing out of the housing when the rotor breaks or cracks. The centrifuging device according to the invention offers ease of cleaning and improved safety. Furthermore, there is no need to worry about the fracture of a coupling portion between the cover and the housing attributable to the repeated opening and closing.

Abstract: The present invention relates to a composition for the treatment of ballast water containing bacteriophage capable of killing specific target bacteria as an active ingredient in order to eliminate or reduce bacteria including pathogenic bacteria present in ballast water, and a biological treatment method of ballast water.

Abstract: The present invention relates to a PCR primer facilitating hot-start PCR by suppressing non-specific amplification at room temperature and at the same time capable of reducing significantly non-specific amplification by dominating the amplification of the PCR product rather than the amplification of the original template from the third PCR cycle, more precisely a PCR primer prepared by additionally inserting the reverse-complementary sequence to a certain region starting from the 5?-start site of the 5?-terminus of the original primer which is composed of priming sequence to anneal to a PCR template into the 5?-terminus of the original primer and a PCR method using the same.

Abstract: The present invention relates to a kit for screening and establishing optimal amplification condition for individual PCR using a dried-formulated PCR reagent which is composed of different combinations of various components affecting PCR result, to provide a method for screening and establishment of optimal amplification in PCR constructed with a dried-formulated PCR reagent. According to the present invention, researchers can perform PCR under the optimal amplification conditions appropriate for individual PCR even with a PCR-related product constructed from a dried-formulated PCR reagent, suggesting that a unique target gene can be efficiently amplified by PCR constructed with a dried-formulated PCR reagent under the more appropriate conditions.